{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:46:41Z","timestamp":1789778801937,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.semarthrit.2017.03.005","type":"journal-article","created":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T21:06:31Z","timestamp":1489007191000},"page":"288-294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients"],"prefix":"10.1016","volume":"47","author":[{"given":"Yvan","family":"Jamilloux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur","family":"Cohen-Aubart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chapelon-Abric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Maucort-Boulch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Marquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"P\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Bouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Deroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bielefeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Bouvry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Noel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Bienvenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Proux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Vukusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Sarrot-Reynauld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Iwaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahir","family":"Amoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Broussolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Valeyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"S\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2017.03.005_bib1","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"Valeyre","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib2","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1183\/09031936.00060612","article-title":"Established and experimental medical therapy of pulmonary sarcoidosis","volume":"41","author":"Baughman","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1183\/09031936.00055213","article-title":"Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis","volume":"43","author":"Vorselaars","year":"2014","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.semarthrit.2017.03.005_bib4","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0012-3692(15)50471-6","article-title":"Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial","volume":"128","author":"Baughman","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib5","first-page":"76","article-title":"Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them","volume":"25","author":"Baughman","year":"2008"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib6","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib7","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/09031936.00051907","article-title":"Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial","volume":"31","author":"Judson","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib8","first-page":"201","article-title":"A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis","volume":"23","author":"Rossman","year":"2006","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.semarthrit.2011.12.006","article-title":"Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review","volume":"42","author":"Maneiro","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib10","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jaad.2012.10.056","article-title":"A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis","volume":"68","author":"Pariser","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00417-011-1844-0","article-title":"Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis","volume":"250","author":"Erckens","year":"2012","journal-title":". Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib12","first-page":"46","article-title":"Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis","volume":"31","author":"Sweiss","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib13","first-page":"149","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis. American Thoracic Society\/European Respiratory Society\/World Association of Sarcoidosis and Other Granulomatous Disorders","volume":"16","author":"Hunninghake","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/qjmed\/92.2.103","article-title":"Central nervous system sarcoidosis\u2014diagnosis and management","volume":"92","author":"Zajicek","year":"1999","journal-title":"QJM"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib15","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1183\/09031936.00169413","article-title":"Association of the TNF-\u03b1 G-308A polymorphism with TNF-inhibitor response in sarcoidosis","volume":"43","author":"Wijnen","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.semarthrit.2015.05.010","article-title":"Anti-TNF-\u03b1 therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients","volume":"45","author":"Riancho-Zarrabeitia","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib17","first-page":"49","article-title":"C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis","volume":"27","author":"Sweiss","year":"2010","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.rmed.2015.11.007","article-title":"A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients","volume":"110","author":"Baughman","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib19","first-page":"509","article-title":"Long-term outcome of infliximab in severe chronic and refractory systemic sarcoidosis: a report of 16 cases","volume":"33","author":"Chapelon-Abric","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib20","first-page":"91","article-title":"Practical eminence and experience-based recommendations for use of TNF-\u03b1 inhibitors in sarcoidosis","volume":"31","author":"Drent","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/mus.20683","article-title":"Granulomatous myositis: a clinical study of thirteen cases","volume":"35","author":"Le Roux","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib22","first-page":"413","article-title":"Effects of adalimumab administration in bio-na\u00efve and bio-switch rheumatoid arthritis patients in daily clinical practice: two-year results from single center","volume":"104","author":"Tashiro","year":"2013","journal-title":"Fukuoka Igaku Zasshi"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/01.MIB.0000438248.14218.1d","article-title":"Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn\u05f3s disease","volume":"20","author":"Brandse","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u05f3s disease: multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2016.04.011","article-title":"Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab","volume":"115","author":"Crommelin","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib26","first-page":"1","article-title":"Biologic therapies in the treatment of sarcoidosis","volume":"3","author":"Saketkoo","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases","volume":"53","author":"Jani","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.rmed.2013.11.019","article-title":"The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial","volume":"108","author":"Judson","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib30","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.rmr.2010.06.011","article-title":"Infliximab treatment for chronic sarcoidosis\u2014a case series","volume":"27","author":"Jounieaux","year":"2010","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.semarthrit.2017.03.005_bib31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur Respir J"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216303742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216303742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T18:29:02Z","timestamp":1535999342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017216303742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0049017216303742"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.03.005","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}